{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:48:22Z","timestamp":1780735702193,"version":"3.54.1"},"reference-count":46,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>The most appropriate steroids to measure for the diagnosis of hyperandrogenism in polycystic ovary syndrome (PCOS) are still open to debate but should preferably be measured using a high-quality method such as liquid chromatography tandem mass spectrometry (LC-MS\/MS). Measurement of testosterone is recommended in all of the current clinical guidelines but other steroids, such as androstenedione and dehydroepiandrosterone sulfate (DHEAS), have also been shown to be useful in diagnosing PCOS and may give additional information on metabolic risk. The 11-oxygenated steroids, and in particular 11KT derived mainly from the adrenal gland, are also increasing in prominence and have been shown to be the dominant androgens in this condition. Polycystic ovary syndrome is a complex syndrome and it is not surprising that each of the clinical phenotypes are associated with different patterns of steroid hormones; it is likely that steroid profiling with LC-MS\/MS may be better at identifying hyperandrogensim in each of these phenotypes. Research into PCOS has been hampered by the small sample size of clinical studies previously undertaken and larger studies, preferably using LC-MS\/MS profiling of steroids, are needed<\/jats:p>","DOI":"10.3390\/medsci7070078","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:28:28Z","timestamp":1562844508000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Steroid Mass Spectrometry for the Diagnosis of PCOS"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0684-9318","authenticated-orcid":false,"given":"Brian","family":"Keevil","sequence":"first","affiliation":[{"name":"Biochemistry Dept, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Rd, Manchester, M23 9LT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jc.2018-00241","article-title":"Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline","volume":"103","author":"Martin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1210\/jc.2017-02426","article-title":"Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women","volume":"103","author":"Elhassan","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11154-007-9054-0","article-title":"The adrenal and polycystic ovary syndrome","volume":"8","author":"Yildiz","year":"2007","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2265.2005.02256.x","article-title":"Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS)","volume":"62","author":"Kumar","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.2174\/1381612822666160719105808","article-title":"Advances in the Diagnosis and Treatment of PCOS","volume":"22","author":"Carmina","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1530\/EJE-09-0741","article-title":"Defining hyperandrogenism in polycystic ovary syndrome: Measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots","volume":"162","author":"Barth","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1210\/jc.2009-1908","article-title":"Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?","volume":"95","author":"Holm","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1530\/EJE-11-0482","article-title":"Assessment of androgen concentration in women: Liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results","volume":"165","author":"Janse","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Keefe, C.C., Goldman, M.M., Zhang, K., Clarke, N., Reitz, R.E., and Welt, C.K. (2014). Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093805"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/jc.2014-1307","article-title":"How do we measure hyperandrogenemia in patients with PCOS?","volume":"99","author":"Keevil","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jc.2013-3399","article-title":"yperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: The utility of serum androstenedione","volume":"99","author":"Taylor","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/humrep\/dey243","article-title":"Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes","volume":"33","author":"Gunness","year":"2018","journal-title":"Hum. Reprod. (Oxf. Engl.)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mce.2016.08.014","article-title":"A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids","volume":"441","author":"Pretorius","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mce.2013.07.006","article-title":"11beta-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: A putative role in castration resistant prostate cancer?","volume":"377","author":"Storbeck","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0015-0282(16)55152-8","article-title":"The ratio of androstenedione:11 beta-hydroxyandrostenedione is an important marker of adrenal androgen excess in women","volume":"58","author":"Carmina","year":"1992","journal-title":"Fertil. Steril."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0015-0282(16)55317-5","article-title":"11 beta-hydroxyandrostenedione in plasma, follicular fluid, and granulosa cells of women with normal and polycystic ovaries","volume":"58","author":"Owen","year":"1992","journal-title":"Fertil. Steril."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1210\/jc.2016-3285","article-title":"11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome","volume":"102","author":"Kempegowda","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.clinbiochem.2016.04.009","article-title":"LC-MS\/MS analysis of steroids in the clinical laboratory","volume":"49","author":"Keevil","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"D1","DOI":"10.1530\/EJE-15-0338","article-title":"Mass spectrometry and immunoassay: How to measure steroid hormones today and tomorrow","volume":"173","author":"Taylor","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1210\/jc.2014-2258","article-title":"Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond","volume":"99","author":"Monaghan","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1210\/jc.2013-3375","article-title":"Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism","volume":"98","author":"Handelsman","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1210\/jc.2014-3424","article-title":"Editorial: The new instructions to authors for the reporting of steroid hormone measurements","volume":"99","author":"Wierman","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13029","DOI":"10.1111\/eci.13029","article-title":"Certified testosterone immunoassays for hyperandrogenaemia","volume":"48","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1210\/jc.2015-2807","article-title":"Implications of Androgen Assay Accuracy in the Phenotyping of Women with Polycystic Ovary Syndrome","volume":"101","author":"Tosi","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.steroids.2008.07.003","article-title":"The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders","volume":"73","author":"Bhasin","year":"2008","journal-title":"Steroids"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/0004563215621096","article-title":"A direct assay for the routine measurement of testosterone, androstenedione, dihydrotestosterone and dehydroepiandrosterone by liquid chromatography tandem mass spectrometry","volume":"53","author":"Owen","year":"2016","journal-title":"Ann. Clin. Biochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1210\/jc.2013-1381","article-title":"Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women","volume":"98","author":"Fanelli","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchromb.2018.03.033","article-title":"The utility of ultra-high performance supercritical fluid chromatography-tandem mass spectrometry (UHPSFC-MS\/MS) for clinically relevant steroid analysis","volume":"1085","author":"Storbeck","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1210\/jc.2018-02527","article-title":"11-Oxygenated C19 Steroids Do Not Decline with Age in Women","volume":"104","author":"Nanba","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.steroids.2010.10.010","article-title":"Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry","volume":"76","author":"Rothman","year":"2011","journal-title":"Steroids"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e22699","DOI":"10.1002\/jcla.22699","article-title":"Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements","volume":"33","author":"Yang","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/humrep\/dew328","article-title":"Performance of mass spectrometry steroid profiling for diagnosis of polycystic ovary syndrome","volume":"32","author":"Handelsman","year":"2017","journal-title":"Hum. Reprod. (Oxf. Engl.)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1210\/jc.2015-2123","article-title":"Androgen Profile Through Life in Women with Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study","volume":"100","author":"Pinola","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/EC-17-0051","article-title":"Longitudinal analyses of the steroid metabolome in obese PCOS girls with weight loss","volume":"6","author":"Reinehr","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1210\/jc.2015-4009","article-title":"Defining Hyperandrogenism in Women with Polycystic Ovary Syndrome: A Challenging Perspective","volume":"101","author":"Pasquali","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"14156","DOI":"10.1038\/s41598-017-14534-2","article-title":"Steroid hormone profiling in obese and nonobese women with polycystic ovary syndrome","volume":"7","author":"Deng","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mce.2019.01.020","article-title":"Oxidative stress increases the 17,20-lyase-catalyzing activity of adrenal P450c17 through p38alpha in the development of hyperandrogenism","volume":"484","author":"Zhu","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dhayat, N.A., Marti, N., Kollmann, Z., Troendle, A., Bally, L., Escher, G., Gr\u00f6ssl, M., Ackermann, D., Ponte, B., and Pruijm, M. (2018). Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203903"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1210\/jc.2014-2523","article-title":"Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome","volume":"100","author":"Munzker","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/cen.13299","article-title":"High salivary testosterone-to-androstenedione ratio and adverse metabolic phenotypes in women with polycystic ovary syndrome","volume":"86","author":"Munzker","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1507\/endocrj.EJ18-0212","article-title":"11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome","volume":"65","author":"Yoshida","year":"2018","journal-title":"Endocr. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/a-0806-8281","article-title":"Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis","volume":"51","author":"Amiri","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1530\/EC-18-0417","article-title":"Diurnal variation of steroid hormones and reference intervals using mass spectrometric analysis","volume":"7","author":"Parikh","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cca.2017.05.002","article-title":"Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS\/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status","volume":"470","author":"Eisenhofer","year":"2017","journal-title":"Clin. Chim. Acta"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/7\/7\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:04:26Z","timestamp":1760187866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/7\/7\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["medsci7070078"],"URL":"https:\/\/doi.org\/10.3390\/medsci7070078","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]}}}